FLT3 and acute myeloid leukemia: However, investigated AML cases that relapse on chemotherapy in addition to Midostaurin in their treatment protocols; may still respond to other newer inhibitors, illustrating that Midostaurin's efficacy may be due to hampering other targets than FLT3 and that several Midostaurin resistance mechanisms present of which FLT3 mutations are not of the central authority [13].